MedTrace Logo

Long Term Follow-Up for Safety of AVR-RD-02

NCT06488261 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2025-07-22

No results posted yet for this study

Summary

The goal of this observational study is to assess the safety and tolerability of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).

Conditions

  • Gaucher Disease

Interventions

BIOLOGICAL

AVR-RD-02

No study drug is administered in this study. Subjects who received AVR-RD-02 in a separate parent trial will be evaluated in this trial for long-term safety.

Sponsors & Collaborators

  • John Bernat

    lead OTHER

Principal Investigators

  • John A. Bernat, MD, PhD · University of Iowa

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2037-06-30
Completion
2037-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06488261 on ClinicalTrials.gov